Patent EP0237833A2 successfully refreshed from Google Patents.
EP0237833A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Solution-phase hybridization assay for detecting polynucleotide sequences
Assignee: Bayer Corp
•
Filing: 1987-02-24
•
Granted: —
•
Expires: 2007-02-24
Abstract
Abstract A process for determining the presence of a particular nucleic acid sequence in a test sample comprising (a) chemically modifying nucleic acids in the test sample either to introduce a label or a reactive site in a manner that supports their hybridizability, (b) contacting under hybridization conditions the chemically modified sample nucleic acids with a hybridizable nucleic acid probe which either, when the sample nucleic acids have been modified to introduce a label, carrys a reactive site or, when the sample nucleic acids have been modified to introduce a reactive site, is labeled, (c) contacting the solution resulting from step (b) with a immobilized form of a reactive partner to the reactive site to form a stable bond with the reactive site on the sample nucleic acids or the probe respectively, (d) separating the resulting immobilized fraction from the remaining solution, and (e) determining the presence of the label in the separated immobilized fraction or a decrease in the label in the remaining solution.
Inventors
- 👤 Nanibhushan Dattagupta
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-31 06:34
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/02; C12Q1/04; C12Q1/16; C07; C07H; C07H21/00; C12Q1/68; C12Q1/6813
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
164 words
A process for determining the presence of a particular nucleic acid sequence in a test sample comprising (a) chemically modifying nucleic acids in the test sample either to introduce a label or a reactive site in a manner that supports their hybridizability, (b) contacting under hybridization conditions the chemically modified sample nucleic acids with a hybridizable nucleic acid probe which either, when the sample nucleic acids have been modified to introduce a label, carrys a reactive site or, when the sample nucleic acids have been modified to introduce a reactive site, is labeled, (c) contacting the solution resulting from step (b) with a immobilized form of a reactive partner to the reactive site to form a stable bond with the reactive site on the sample nucleic acids or the probe, respectively, (d) separating the resulting immobilized fraction from the remaining solution, and (e) determining the presence of the label in the separated immobilized fraction or a decrease in the label in the remaining solution.
Claim 2
Dependent Claim
164 words
A process for determining the presence of a particular nucleic acid sequence in a test sample comprising (a) chemically modifying nucleic acids in the test sample either to introduce a label or a reactive site in a manner that supports their hybridizability, (b) contacting under hybridization conditions the chemically modified sample nucleic acids with a hybridizable nucleic acid probe which either, when the sample nucleic acids have been modified to introduce a label, carrys a reactive site or, when the sample nucleic acids have been modified to introduce a reactive site, is labeled, (c) contacting the solution resulting from step (b) with a immobilized form of a reactive partner to the reactive site to form a stable bond with the reactive site on the sample nucleic acids or the probe, respectively, (d) separating the resulting immobilized fraction from the remaining solution, and (e) determining the presence of the label in the separated immobilized fraction or a decrease in the label in the remaining solution.
Claim 3
Dependent Claim
39 words
A process according to claim 1, wherein the chemical modification of the sample nucleic acids to introduce said label or said reactive site is accomplished by reaction with a photochemically reactive reagent comprising said label or reactive site, respectively.
Claim 4
Dependent Claim
42 words
A process according to any of claims 1 and 2, wherein the immobilized form of the reactive partner comprises a solid support to which the reactive group is attached and the reactive site is a binding site capable of specific noncovalent binding.
Claim 5
Dependent Claim
37 words
A process according to any of claims 1 to 3, wherein the binding site is biotin or a hapten and wherein the immobilized reactive partner is an immobilized form of avidin or an anti-hapten antibody reagent, respectively.
Claim 6
Dependent Claim
37 words
A process according to any of claims 1 to 4, wherein the label is selected from the group consisting of an enzymatically active group, a fluorescer, a cbromophore, a luminescer, a specifically bindable ligand end a radioisotope.
Claim 7
Dependent Claim
31 words
A process according to any of claims 1 to 5, wherein the label is a specifically bindable ligand and its presence is determined by binding with a labeled binding partner therefor.
Claim 8
Dependent Claim
28 words
A process according to any of claims 1 to 6, wherein the particular sequence of interest is characteristic of the presence of absence of a particular genetic disorder.
Claim 9
Dependent Claim
49 words
A kit for determining the presence of a particular nucleic acid sequence in a test sample comprising a) an immobilizable form of a reactive partner, and b) a hybridizable nucleic acid probe which is labeled or carriers a reactive site which forms a stable bond with said reactive partner.
Claim 10
Dependent Claim
49 words
A kit for determining the presence of a particular nucleic acid sequence in a test sample comprising a) an immobilizable form of a reactive partner, and b) a hybridizable nucleic acid probe which is labeled or carriers a reactive site which forms a stable bond with said reactive partner.
Claim 11
Dependent Claim
48 words
A kit according to claim 15, which further comprises a reagent reactable with nucleic acids in the test sample to introduce, in a manner that supports their hybridizability, (i) a label, when said probe carriers said reactive site, or (ii) said reactive site, when said probe is labeled.
Claim 12
Dependent Claim
28 words
Use of the process according to any of claims 1 to 7 or of the kit according to claims 8 and 9 in the detection of genetic disorders.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.